Fig 1: The HIC1-TGFB1-CXCL5 loop is associated with disease progression in patients with PCa.a Representative IHC images of TMA showing the corresponding expression of stromal CD206 and CXCL5 in PCa tumor tissues. Scale bar: 200 (upper panel) and 50 μm (lower panel). b Analysis of a number of CD206 staining cells in stroma between normal and tumor, stage I–II and stage III–IV tissues. c Analysis of CXCL5 staining in stroma between normal and tumor, stage I–II and stage III–IV tissues (P values were obtained using two-tailed Student’s t tests. The Whiskers connect the minimum and the maximum values to the Box; *P < 0.05, **P < 0.01, ***P < 0.001; ****P < 0.0001). d The correlation between CD206+ cells and CXCL5 expression levels in stroma. Spearman r = 0.541. The correlation was calculated by Spearman correlation analysis. e IHC staining of stromal CD206 in primary tumor and metastatic lymph nodes from the same patient. Black arrows represent M2 macrophages. Lower panel: quantitative analysis of infiltrating macrophages in primary tumor compared with infiltrating macrophages in metastatic LNs. P values were obtained using two-way ANOVA. Scale bar: 200 (upper panel) and 50 μm (lower panel). f Schematic model shows how HIC1-mediated crosstalk between cancer cells, macrophages, and fibroblasts promotes in the process of PCa progression. Conditional deletion of Hic1 and Pten in mouse prostate epithelium contributes to the malignant phenotype of PCa. HIC1-induced higher TGF-β secretion in TME promotes M2 macrophage activation and up-regulates CXCR4 expression by inducing c-Myc pathway. Meanwhile, TGF-β activates NFs into CAFs to secrete higher CXCL12, which binds to CXCR4 on M2 macrophages. Upon the interaction with CAFs, M2 macrophages in turn enhance the malignant phenotypes of PCa through induction of EMT by activating the CXCL5/CXCR2 chemokine axis.
Fig 2: TOE inhibited the cytokine‐receptor signalling in DSS‐induced colitis. A, B, GSEA identification of the 11 major genes in cytokine‐receptor signalling in TOEH group as compared with the DSS group. C, D, RT‐PCR and IHC analysis of the expression levels of CCL20, CXCL5, CCR6 and CXCL1 in TOEH and DSS groups. *P < .05, **P < .01, ***P < .001
Fig 3: CXCL5 was a target of miR-4766-5p. a The binding sites between miR-4766-5p and CXCL5 were shown. b Dual luciferase activity of CXCL5-WT/MUT was tested in GC cell lines by performing dual luciferase reporter assays after transfected with miR-4766-5p mimics or miR-NC. c The expression of CXCL5 was examined with qRT-PCR in normal tissues and tumor tissues. d The mRNA level of CXCL5 was examined in GC cells through performing qRT-PCR. e The protein level of CXCL5 was examined in GC cells through performing western blot analysis. *P < 0.05 compared with the Normal, GES or miR-NC group
Fig 4: Validation of correlation between CXCL5 expression and infiltration of M2 polarized macrophages, neutrophils and IgG+ plasma cells in pancreatic cancer from data of TCGA and GTEx. (A) Correlation analysis between CXCL5 and CD163 (R=0.26, p=0.00046, Spearman correlation analysis); (B) Correlation analysis between CXCL5 and CD15 (R=0.46, p=8.1× e-7, Spearman correlation analysis). (C) Correlation analysis between CXCL5 and IGHG1 (R=0.21, p=0.0039, Spearman correlation analysis). (D) Correlation analysis between CXCL5 and IGHG2 (R=0.2, p=0.0086, Spearman correlation analysis). Data was obtained from the GEPIA (http://gepia.cancer-pku.cn/).
Fig 5: Correlation between CXCL5 expression and clinicopathological features and prognosis. (A-C) Expression of CXCL5 in tumor tissues with different T stages, N stages and differentiation statuses. (D) The influence of tumoral CXCL5 expression on OS (p=0.001, log-rank test). (E) The multivariate Cox regression analysis showed that CXCL5 expression was an independent factor in the high CA242 subgroup (HR=2.047, p=0.004). (F) PDAC patients with high CA242 levels had worse OS than those with low CA242 levels (p=0.006). (G) The combination of CXCL5 expression and CA242 was a good prognostic factor (p<0.0001). (H) The results from SurvExpress, showed that high CXCL5 expression was associated with poor OS in PDAC patients (p=0.00022). (I) Comparison of CXCL5 expression between patients in the “High Risk” group and those in the “Low Risk” group through the SurvExpress program (p=3.32e-32). (J) The prognostic value of CXCL5 mRNA expression in the Kaplan-Meier plotter dataset (HR=1.6, p=0.02664).
Supplier Page from Abcam for Anti-CXCL5 antibody